Mirati Therapeutics Competitors and Similar CompaniesClear all
Mirati Therapeutics's competitors and similar companies include Verastem Oncology, OncoStem Diagnostics, Tetherex and Adagene.
 Mirati Therapeutics Mirati Therapeutics is an oncology company that designs and develops targeted therapies to address the genetic drivers of cancer. |  Verastem Oncology Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. |  OncoStem Diagnostics OncoStem Diagnostics is a diagnostic oncology company focused on discovering and developing novel tests for improved treatment planning. |  Tetherex Tetherex Pharmaceuticals Corp is a biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases. |  Adagene Adagene is an antibody discovery and development biotechnology company specializing in oncology immunotherapy. | |
Founding Date | Founding Date 2013 | Founding Date 2010 | Founding Date 2011 | Founding Date 2014 | Founding Date 2012 |
Type | Type Subsidiary | Type Public | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ Zug, CH | Locations Needham, US HQ Walsrode, DE | Locations Bengaluru, IN HQ | Locations Oklahoma City, US HQ Morrisville, US | Locations Suzhou, CN HQ San Diego, US San Francisco, US |
Employees | Employees 15810% decrease | Employees 7328% increase | Employees 264% increase | Employees N/A | Employees 174 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 144.9 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 137.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $12.4m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $18.1m (FY, 2023) |
Cost of goods | Cost of goods $600k (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $11.8m (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $21.6m (FY, 2023) |
Net income | Net income ($740.9m) (FY, 2022) | Net income ($87.4m) (FY, 2023) | Net income N/A | Net income N/A | Net income ($18.9m) (FY, 2023) |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 6m (over 7 years ago) | Latest funding round $ 43m (almost 7 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised N/A | Total funding raised $ 170m | Total funding raised $ 7m | Total funding raised $ 46.2m | Total funding raised $ 155m |
For sources of this data, please see the company profile
View Company Profiles
Verastem Oncology
HQ
Needham, US
Employees
73↑ 28% increase
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.
View companyOncoStem Diagnostics
HQ
Bengaluru, IN
Employees
26↑ 4% increase
OncoStem Diagnostics is a diagnostic oncology company focused on discovering and developing novel tests for improved treatment planning.
View companyTetherex
HQ
Oklahoma City, US
Tetherex Pharmaceuticals Corp is a biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases.
View companyAdagene
HQ
Suzhou, CN
Employees
174
Adagene is an antibody discovery and development biotechnology company specializing in oncology immunotherapy.
View company